Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

June 30, 2026

Conditions
NSCLC, Stage III
Interventions
DRUG

Durvalumab Injection [Imfinzi]

Durvalumab fixed dose of 1,500 mg

RADIATION

Thoracic Radiotherapy (TRT) conventionally

Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks

RADIATION

Thoracic Radiotherapy (TRT) hypofractionated

Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks

Trial Locations (14)

13359

DRK Kliniken Berlin-Mitte, Berlin

33332

Onkodok GmbH, Gütersloh

37075

Universitätsmedizin Göttingen, Göttingen

41063

Kliniken Maria Hilf GmbH, Mönchengladbach

48153

Gemeinschaftspraxis für Hämatologie und Onkologie, Münster

51109

Kliniken der Stadt Köln gGmbH, Lungenklinik Merheim, Cologne

52074

Universitätsklinikum Aachen, Aachen

55131

Universitätsmedizin Mainz, Mainz

58675

Lungenklinik Hemer, Pneumologie und Thorakale Onkologie, Hemer

63069

Sana Klinikum Offenbach GmbH, Offenbach

69126

Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg

71640

Klinikum Ludwigsburg, Ludwigsburg

76137

Vincentius-Diakonissen-Kliniken gAG, Karlsruhe

77654

Pi.Tri-Studien GmbH, Offenburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Thoraxklinik-Heidelberg gGmbH

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER